Full Breakdown
Galleri Blood Test Fails to Meet Expectations in Major Study
2/24/2026, 12:29:09 AM
Overview of the Study's Findings
The Galleri blood test, developed by Grail, aimed to detect cancer at earlier stages by identifying fragments of cancer DNA in the blood. However, a significant study conducted in collaboration with the U.K.'s National Health Service (NHS) revealed that the test did not achieve its primary goal of reducing late-stage cancer diagnoses. The study, which followed 142,000 healthy adults aged 50 to 77 over three years, found no statistically significant decrease in the number of Stage 3 or Stage 4 cancers among participants who received the Galleri test compared to those who did not. Grail had anticipated a 20% reduction in advanced cancer cases, a target that was ultimately missed.
Company Response and Stock Impact
Following the announcement of the study results, Grail's stock plummeted by over 45%. The company, which has sold nearly 500,000 Galleri tests since its introduction in 2021, reported a revenue increase of 17% year-over-year, totaling $147.2 million. Despite the disappointing trial outcomes, Grail executives expressed optimism about certain findings, noting a favorable trend toward fewer Stage 4 cancers and an increase in Stage 3 diagnoses, suggesting that some cancers might have been detected slightly earlier.
Expert Opinions and Criticism
Experts have expressed skepticism regarding the study's results. Dr. Richard Houlston, a cancer genetics expert, indicated that the findings do not support the test's rollout within the American healthcare system. Dr. Adewole Adamson, a cancer researcher, stated, “This study failed — end of story,” emphasizing the lack of significant results. Additionally, Dr. Daniel Hayes highlighted the limitations of blood tests, noting that they can lead to false alarms without definitive follow-up actions.
Implications for Future Research and Approval
The failure of the Galleri test to meet its primary endpoint raises questions about its potential for FDA approval, which Grail is currently pursuing. The results may complicate the approval process, as experts consider the implications of the study sobering for the field of early cancer detection. Grail plans to extend the trial's follow-up period by 6 to 12 months to gather more data, hoping to demonstrate a stronger effect over time.
Conclusion
The Galleri blood test's inability to significantly reduce late-stage cancer diagnoses in a major study has raised concerns about its efficacy and future in cancer screening. While Grail remains committed to its product and plans to enhance its educational outreach, the mixed results underscore the challenges faced in the development of reliable early cancer detection methods.
